0001980223-24-000002.txt : 20240422 0001980223-24-000002.hdr.sgml : 20240422 20240422161548 ACCESSION NUMBER: 0001980223-24-000002 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06c ITEM INFORMATION: Investment Company Act Section 3(c) ITEM INFORMATION: Section 3(c)(5) FILED AS OF DATE: 20240422 DATE AS OF CHANGE: 20240422 EFFECTIVENESS DATE: 20240422 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NexPoint Life Sciences II DST CENTRAL INDEX KEY: 0001980223 ORGANIZATION NAME: IRS NUMBER: 921218022 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-484852 FILM NUMBER: 24861376 BUSINESS ADDRESS: STREET 1: 300 CRESCENT COURT STREET 2: SUITE 700 CITY: DALLAS STATE: TX ZIP: 75201 BUSINESS PHONE: 833-697-6246 MAIL ADDRESS: STREET 1: 300 CRESCENT COURT STREET 2: SUITE 700 CITY: DALLAS STATE: TX ZIP: 75201 D/A 1 primary_doc.xml X0708 D/A LIVE 0001980223 NexPoint Life Sciences II DST 300 CRESCENT COURT SUITE 700 DALLAS TX TEXAS 75201 833-697-6246 DELAWARE None None Other Delaware Statutory Trust true 2023 N/A NexPoint Real Estate Advisors IV, L.P. 300 Crescent Court Suite 700 Dallas TX TEXAS 75201 Executive Officer Sponsor of the Issuer Matthew Goetz 300 Crescent Court Suite 700 Dallas TX TEXAS 75201 Executive Officer Authorized Signatory of the Issuer N/A NREA Life Sciences II, LLC 300 Crescent Court Suite 700 Dallas TX TEXAS 75201 Executive Officer Manager and Signatory Trustee of the Issuer N/A NREA LS II Investment Co, LLC 300 Crescent Court Suite 700 Dallas TX TEXAS 75201 Executive Officer Contributor of the Issuer Matt McGraner 300 Crescent Court Suite 700 Dallad TX TEXAS 75201 Executive Officer Authorized Signatory of the Issuer Other Real Estate Decline to Disclose 06c 3C 3C.5 true 0001980223-24-000001 2023-06-20 false true false 100000 Emerson Equity LLC 130032 None None 155 Bovet Road Suite 725 San Mateo CA CALIFORNIA 94402 CA CALIFORNIA FL FLORIDA NY NEW YORK false Centaurus Financial, Inc. 30833 None None 2300 E. Katella Avenue Suite 200 Anaheim CA CALIFORNIA 92806 AZ ARIZONA CA CALIFORNIA CO COLORADO UT UTAH false Arkadios Capital 282710 None None 309 East Paces Ferry Road Suite 1000 Atlanta GA GEORGIA 30305 CA CALIFORNIA false Coastal Equities, Inc. 23769 None None 120 N. Orange Street Suite 729 Wilmington DE DELAWARE 19801 CA CALIFORNIA UT UTAH false DMK Advisor Group, Inc. 41067 None None 17961 Hunting Bow Circle Suite 102 Lutz FL FLORIDA 33558 OR OREGON false Concorde Investment Services, LLC 151604 None None 19500 Victor Parkway Suite 550 Livonia MI MICHIGAN 48152 AZ ARIZONA CA CALIFORNIA FL FLORIDA KY KENTUCKY MA MASSACHUSETTS PA PENNSYLVANIA UT UTAH false Great Point Capital LLC 114203 None None 200 West Jackson Blvd. Suite 1000 Chicago IL ILLINOIS 60606 MO MISSOURI false Patrick Capital Markets, LLC 16518 None None 11152 South Town Square St. Louis MO MISSOURI 63123 GA GEORGIA ME MAINE false Infinity Financial Services 144302 None None 212 9th Street Suite 202 Oakland CA CALIFORNIA 94607 TX TEXAS false Lightpath Capital, Inc. 34617 None None 1560 E. Southlake Blvd. Suite 100 Southlake TX TEXAS 76092 CA CALIFORNIA false DFPG Investments, LLC 155576 None None 9017 S. Riverside Drive Suite 210 Sandy UT UTAH 84070 TN TENNESSEE false 40489695 19409113 21080582 Regarding Item 11, the Issuer may accept smaller investments in the Sponsor's sole discretion. false 54 3542849 true 0 true Sales Commissions include estimates of the maximum amount of Selling Commissions and Dealer Fees that may be paid. 792938 true Item 16 is an estimate of offering expenses and acquisition fees that may accrue to one or more Related Persons. false NexPoint Life Sciences II DST /s/Brian Mitts Brian Mitts Authorized Signatory of the Issuer 2024-04-22